Small p53 derived peptide suitable for robust nanobodies dimerization - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Immunological Methods Année : 2021

Small p53 derived peptide suitable for robust nanobodies dimerization

Résumé

Bivalent VHHs have been shown to display better functional affinity compared with their monovalent counterparts. Bivalency can be achieved either by inserting a hinge region between both VHHs units or by using modules that lead to dimerization. In this report, a small self-associating peptide originating from the tetramerization domain of p53 was developed as a tool for devicing nanobody dimerization. This E3 peptide was evaluated for the dimerization of an anti-eGFP nanobody (nano-eGFP-E3) whose activity was compared to a bivalent anti-eGFP constructed in tandem using GS rich linker. The benefit of bivalency in terms of avidity and specificity was assessed in different in vitro and in cellulo assays. In ELISA and SPR, the dimeric and tandem formats were nearly equivalent in terms of gain of avidity compared to the monovalent counterpart. However, in cellulo, the nano-eGFP-E3 construct showed its superiority over the tandem format in terms of specificity with a highest and better ratio signal-to-noise. All together, the E3 peptide provides a universal suitable tool for the construction of dimeric biomolecules, in particular antibody fragments with improved functional affinity.

Domaines

Immunologie
Fichier principal
Vignette du fichier
islandora_121049.pdf (13.44 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03370331 , version 1 (07-10-2021)

Identifiants

Citer

Frank Dietsch, Yves Nominé, Audrey Stoessel, Camille Kostmann, Anna Bonhoure, et al.. Small p53 derived peptide suitable for robust nanobodies dimerization. Journal of Immunological Methods, 2021, 498, pp.113144. ⟨10.1016/j.jim.2021.113144⟩. ⟨hal-03370331⟩
51 Consultations
95 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More